Appleyard, Maria Virginia C L <br/><br/>
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.  [electronic resource] 

 -  International journal of cancer  Jan 2009 
 - 465-72 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.23938  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Cyclin-Dependent Kinase Inhibitor p27--metabolism<br/>Cyclin-Dependent Kinases--metabolism<br/>Doxorubicin--administration & dosage<br/>Drug Synergism<br/>Female<br/>Humans<br/>Mammary Neoplasms, Animal--drug therapy<br/>Mice<br/>Mice, Nude<br/>Neoplasm Transplantation<br/>Protein Kinase Inhibitors--administration & dosage<br/>Purines--administration & dosage<br/>Roscovitine